These inhibitors have shown efficacy not only in ovarian cancer but also in breast, prostate, and pancreatic cancers, particularly in patients with BRCA1/2 mutations or other defects in DNA repair pathways [10,11]. This evidence concerns the gene BRCA1 and ovarian cancer.